JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266329

Human PSMD8 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PSMD8 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 1 and 22 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

26S proteasome non-ATPase regulatory subunit 8, 26S proteasome regulatory subunit RPN12, 26S proteasome regulatory subunit S14, 26S proteasome regulatory subunit p31, AAV38494, HIP6, HYPF, MGC1660, Nin1p, P31, PSMD8_HUMAN, Proteasome (prosome macropain) 26S subunit non ATPase 8, Rpn12

2 Images
Sanger Sequencing - Human PSMD8 knockout HEK-293T cell line (AB266329)
  • Sanger seq

Unknown

Sanger Sequencing - Human PSMD8 knockout HEK-293T cell line (AB266329)

Allele-1 : 22 bp deletion in exon 1

Sanger Sequencing - Human PSMD8 knockout HEK-293T cell line (AB266329)
  • Sanger seq

Unknown

Sanger Sequencing - Human PSMD8 knockout HEK-293T cell line (AB266329)

Allele-2 : 19 bp deletion in exon 1.

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 1 and 22 bp deletion in exon 1

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266329-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266329 Human PSMD8 knockout HEK-293T cell line", "number":"AB266329-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266329-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266329 Human PSMD8 knockout HEK-293T cell line", "number":"AB266329-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PSMD8
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PSMD8 also known as proteasome 26S subunit non-ATPase 8 is a component of the 19S regulatory particle of the proteasome complex. This protein has a molecular mass of approximately 37 kDa. It facilitates protein degradation by recognizing ubiquitin-tagged substrates important for maintaining protein homeostasis. Researchers have identified its expression in various tissues including liver kidney and heart and it plays a significant role in cellular processes that require regulated protein turnover.
Biological function summary

PSMD8 contributes to the assembly and function of the 26S proteasome which is a multi-subunit complex responsible for degrading ubiquitinated proteins. It acts as a part of the regulatory particle enabling substrate recognition and unfolding. Through its function PSMD8 is involved in the ubiquitin-proteasome system which is key in cellular regulation mechanisms such as cell cycle control apoptosis and DNA repair. This highlights its importance in maintaining cell function and integrity.

Pathways

Protein homeostasis and degradation represent important pathways in which PSMD8 participates. It plays a role in the ubiquitin-proteasome pathway interacting with proteins within this system like Rpn11 and Rpt5 which are also parts of the proteasome complex. Additionally the involvement of PSMD8 in the protein degradation pathway links it to the regulation of transcription factors influencing various signaling pathways that control cell proliferation and differentiation.

PSMD8 has implications in neurodegenerative diseases and cancer as disruptions in proteasome functions are often related to these conditions. Altered proteasome activity can lead to the accumulation of misfolded or damaged proteins which is a hallmark of neurodegenerative diseases such as Parkinson's disease. Moreover in cancer PSMD8's role in protein degradation can affect cell cycle regulation working in connection with proteins like p53. These relationships make PSMD8 an interesting target for therapeutic interventions in proteasome-related diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com